We evaluated the efficacy and safety of the conditioning regimen that consisted of TBI and melphalan (L-PAM), followed by hematopoietic SCT (HSCT) in 23 children with advanced hematological malignancies. The median age at HSCT was 9 (range, 2-15) years. The underlying diseases were ALL in 16 patients (5 in CR2, 3 in CR3, 6 in relapse (RP) and 2 in induction failure (IF)), AML in 4 patients (3 in RP and 1 in IF) and non-Hodgkin's lymphoma in 3 patients (1 in CR3, 1 in CR4 and 1 in RP). The stem cell sources were BM for 19 patients and cord blood for 4 patients. All patients received the conditioning regimen that consisted of TBI 12 or 13.2 Gy and L-PAM 210 mg/m 2 . In all, 22 patients engrafted on the median of day 16 (range, 10-23). The regimen was well tolerated and common regimen-related toxicities (RRTs) included grade II stomatitis and grade I hepatic toxicity. The cumulative incidences of RP and TRM were 47.6 and 21.5%, respectively. At a median follow-up of 24.4 months, the probability of disease-free survival was 41.0%. The regimen may provide sufficient anti-leukemic effect without increased RRT for advanced pediatric hematological malignancies.
Introduction
Allogeneic hematopoietic SCT (HSCT) is the only curative treatment for children with chemo-resistant or relapsed hematological malignancies. The treatment outcomes of HSCT for these patients have been extremely poor because of a high incidence of relapse (RP) or persistent disease following HSCT. 1, 2 In addition, the risk for TRM increases as the disease status at HSCT is advanced. [2] [3] [4] Although investigators have attempted to intensify the anti-leukemic effect by adding etoposide or thiotepa to conventional preparative conditioning regimens, such as TBI and CY or BU and CY, the disease-free survival (DFS) rates still do not significantly improve in patients with advanced disease. [3] [4] [5] [6] The incidence of RP after HSCT still remains high. In addition, the intensified conditioning regimens used in these studies were associated with an increased incidence of TRM. These results suggested that the anti-leukemic effect and regimen-related toxicity (RRT) might offset each other.
Melphalan (L-PAM) is an alkylating agent with demonstrated activity against acute leukemia. De Lima et al. 7 reported that 10 patients with acute leukemia who relapsed within 1 year after allogeneic BMT were given L-PAM of 180 mg/m 2 followed by allogeneic PBSCT. In all, 7 of the 10 patients achieved CR, although durable remissions were not observed. The feasibility of L-PAM combined with BU as conditioning regimen has also been demonstrated in pediatric patients in some previous studies. Matsuyama et al. 8 reported a 90% 5-year DFS in 30 children with acute leukemia in CR1 or CR2, after HLA-matched related BMT with a conditioning regimen consisting of oral BU and L-PAM. Small et al. 9 reported the outcome of 43 recipients with advanced hematological malignancies, including pediatric patients, who received HLA-matched related or unrelated HSCT after a conditioning regimen consisting of i.v. BU and L-PAM with tacrolimus and short-course MTX. The 3-year probability of DFS and cumulative incidence of RP were 33 and 36%, respectively, for the entire cohort. On the other hand, L-PAM has been used in a reduced-intensity conditioning regimen 10 or a TBI-based myeloablative regimen in combination with a third agent, such as Ara-C or fludarabine. [11] [12] [13] However, the effectiveness of combined TBI and L-PAM as a conditioning regimen for hematological malignancies has not been previously evaluated in pediatric patients. We herein describe the outcome of allogeneic HSCT for 23 pediatric hematological malignancies, using the conditioning regimen of TBI (12-13.2 Gy) and L-PAM (210 mg/m 2 ). All patients analyzed in this retrospective study were classified with a considerably high-risk disease status, and we evaluated the efficacy and safety of the regimen for these patients.
Patients and methods

Patients and donors
The study included 23 children with advanced hematological malignancies. The characteristics of the patients are shown in Table 1 . The patients consisted of 11 males and 12 females with a median age of 9 (range, 2-15) years at the time of HSCT. The underlying disease and disease status at the time of HSCT were ALL in 16 patients (5 in CR2, 3 in CR3, 6 in RP and 2 in induction failure), AML in 4 patients (3 in RP and 1 in induction failure) and non-Hodgkin's lymphoma in 3 patients (1 in CR3, 1 in CR4 and 1 in RP). The patients with ALL in CR2 were included in this study if they were classified into risk groups S3 or S4 according to the risk category using the Berlin-Frankfurt-Munster protocol for relapsed ALL (The ALL-REZ BFM 96 or 2002). In the protocol, the strategic groups S1-S4 were developed as risk groups that were based on known prognostic factors, such as time and site of RP as well as the blast immunophenotype. The retrospective application of these criteria to previous studies showed that patients in groups S3 and S4 had an EFS of less than 5% by chemotherapy alone and approximately 40% when they were transplanted in CR. When they were transplanted with a high minimal residual disease load (410 À4 leukemic cells) before HSCT, the 5-year EFS and cumulative incidence of RP were 30 and 50%, respectively.
14 On the other hand, the EFS of groups S1 and S2 was approximately 75 and 45% with chemotherapy alone. 15 As the outcomes of HSCT for AML in CR1 or CR2 were previously reported to be relatively favorable, 16, 17 only those AML patients in non-remission at the time of HSCT were analyzed in this study.
The stem cell sources were BM for 19 patients (5 were related and 14 unrelated) and unrelated cord blood for 4 patients. Two patients received BMT from HLA-matched siblings and three patients from HLA one-locus mismatched related donors. In all, 13 of 14 patients received BMT from HLA-matched unrelated donors. Of these 13 patients, 6 patients had one-locus mismatch in HLA-A, B or DRB1 according to high-resolution DNA typing. One patient underwent BMT from HLA one-locus mismatched unrelated donor.
Conditioning regimen and transplantation procedures
The pre-transplant conditioning regimen consisted of TBI 12 or 13.2 Gy and L-PAM 210 mg/m 2 . Until 2004, five patients received TBI of 13.2 Gy given in 11 fractions of 1.2 Gy for 4 consecutive days. Since 2005, by institutional circumstances, TBI of 12 Gy given in 6 fractions of 2 Gy for 3 consecutive days was adopted. All patients received TBI at a dose rate of 8 cGy/min using a 10-MV X-ray with laterally opposed fields. Lung shielding was used to limit the dose to 90% of the total prescribed doses to the lungs and eye shielding was also used to lessen the risk of cataracts. From the next day of the last dose of TBI, L-PAM was administered as 70 mg/m 2 i.v. per day for 3 consecutive days.
For the prophylaxis of GVHD, CsA with or without short-term MTX (sMTX), 15 mg/m 2 on day 1 and 10 mg/ m 2 on days 3, 6 and 11, was used for patients receiving BMT from matched sibling. Mismatched related BM recipients received CsA or tacrolimus (FK506) with sMTX. The 14 unrelated BMT patients received FK506 with sMTX (12 patients) or CsA with sMTX (2 patients). Four patients of unrelated cord blood transplantation received FK506 with sMTX. CsA was given i.v. at a dose of 1.5 mg/ kg twice a day from day À1, and was adjusted to maintain whole blood trough levels at 150-250 ng/mL. FK506 was administered as a continuous i.v. infusion at a dose of 0.02-0.03 mg/kg/day from day À1, and adjusted to maintain the whole blood levels between 10 and 15 ng/mL.
The median nuclear cell count of transplanted BM was 3.0 (range, 0.5-8.2) Â 10 8 per recipient body weight without ex vivo T-cell depletion. The median pre-thawed nuclear cell count of transplanted unrelated cord blood was 4.4 (range, 1.9-7.3) Â 10 7 per recipient body weight. Recombinant human G-CSF was given i.v. to facilitate the engraftment of neutrophils from day 7 and Ig was given weekly for prophylaxis against CMV infection. Fluconazole or micafungin was used for antifungal prophylaxis and acyclovir for prophylaxis against HSV.
Assessment of engraftment, RRT and GVHD Engraftment was defined as the first day the ANC reached 0.5 Â 10 9 /L for 3 consecutive days within 28 days post transplantation. Both the platelets and reticulocytes were considered to be recovered when they reached counts of over 20 Â 10 9 /L and over 1% without transfusion support. RRT was graded according to Bearman's grading system, 18 except that death after day 28 resulting from RRT was scored as grade IV. Toxicity was graded from day 0 to day 28 (and to day 100 for lungs) after HSCT and the maximum toxicity was recorded for each individual organ. When toxicity could be attributed to infection, GVHD or other medications, the toxicity was not scored as RRT. If it was not clear whether a hepatic toxicity was related to the conditioning regimen or other medications such as an antibiotic, that toxicity was scored as RRT. Veno-occlusive disease (VOD) was considered as RRT. The diagnosis and grade of acute GVHD were made based on established clinical criteria. 19 The onset forms and types of chronic GVHD were differentiated according to the published classification. 20 Statistical analysis Surviving patients were followed to 31 December 2009. The DFS was defined from the day of HSCT to the time of RP or to the last follow-up visit for patients in continuous CR. The probabilities of DFS, RP and TRM in the study population were calculated using the Kaplan-Meier methods with the corresponding 95% confidence intervals (CIs).
Results
Engraftment and treatment response
One patient with non-Hodgkin's lymphoma died of septicemia caused by Pseudomonas aeruginosa before engraftment. A total of 22 patients engrafted at a median of day 16 (range, 10-23) and 21 patients had platelet recovery at a median of day 25 (range, 16-57). Reticulocyte recovery was achieved for 22 patients at a median of day 24 (range, 13-41). None of the patients had primary or secondary graft failure.
Eleven patients (six ALL, four AML and one nonHodgkin's lymphoma) had active disease at HSCT and the outcomes of these patients are shown in Table 2 . Ten patients with acute leukemia who had 8-68% blasts in the BM before the start of the conditioning regimen successfully engrafted and achieved CR on day 30, which was confirmed by BM aspiration. Their subsequent remission lasted for 2.0-196.8 (at a median of 11.2) months.
RP and DFS
Eight patients relapsed at a median of 6.5 (range, 2-20) months after HSCT and the cumulative incidence of RP was 47.6% (95% CI, 27.1-77.7%) (Figure 1 ). In all, 3 of 12 patients who were in remission at HSCT relapsed at 16, 17 and 20 months, whereas 5 of 11 patients in non-remission at HSCT relapsed at a median of 3.0 (range, 2.0-10.5) months after transplantation. Overall, 11 patients, including 5 patients who were not in remission at HSCT, are alive and remained in CR at a median follow-up of 24.4 (range, 6.2-196.8) months, and the probability of DFS was 41.0% (95% CI, 18.9-63.1%) (Figure 2) .
RRT, GVHD and other complications RRT was mild or moderate (grade I-II) among the majority of the patients ( Table 3 ). The toxicity of oral mucosa (stomatitis) was the most common side effect observed in all 23 patients. In all, 17 of 23 (74%) patients suffered from grade II stomatitis and required continuous i.v. administration of morphine hydrochloride against oral pain. Hepatic toxicity of grades I or II was observed in 12 patients and one patient with anaplastic large-cell lymphoma developed a fatal VOD, which was scored as grade IV. No other severe toxicities of grade III-IV were observed. Five patients had hemorrhagic cystitis. Of these, the etiologies of hemorrhagic cystitis were BK virus infection in three patients and an adenovirus infection in one patient. Although no hemorrhagic cystitis pathogens were detected in the remaining patient, there seemed to be no relation to the conditioning regimen as the symptom occurred at 30 days following BMT. CMV reactivation occurred in 10 patients, two cases of which evolved into interstitial pneumonia. Four patients developed herpes zoster.
In all, 13 of 22 (59.1%) evaluable patients developed acute GVHD of grade II-IV. Among these, grade III and IV acute GVHD occurred in 5 (22.7%) and 2 (8.7%) patients, respectively. In the 14 patients who received unrelated BMT, 10 patients (71.4%) developed acute GVHD, including 6 (40.0%) with grade II and 4 (28.5%) with grade III. Chronic GVHD occurred in 11 of 21 (52.4%) evaluable patients who survived more than 100 days after HSCT. The types of chronic GVHD were limited in four patients and extensive in seven patients.
TRM occurred in four patients: septicemia caused by P. aeruginosa and VOD in the first 100 days, pulmonary mucormycosis and necrotic encephalitis more than 100 days after HSCT. TRM occurred in 3 (25%) patients among 12 patients who were in remission at HSCT and in 1 (9%) among 11 patients who were not in remission at HSCT. The cumulative incidence of TRM was 21.5% (95% CI, 2.1-40.9%) (Figure 1 ).
Discussion
In this study, we evaluated the efficacy of a novel combination of TBI and L-PAM as a conditioning regimen for HSCT in pediatric patients with advanced hematological malignancies. The regimen was effective enough to eradicate malignant cells and to achieve engraftment. No primary or secondary graft failure was observed and engraftments were achieved within 23 days in all engrafted patients. It is noteworthy that 10 patients with acute leukemia in non-remission status at HSCT achieved CR after the conditioning regimen, and 5 of these patients maintained CR at the time of the most recent follow-up. As a result, a probability of approximately 40% DFS was compared favorably with the outcomes previously reported for HSCT in pediatric advanced disease. [4] [5] [6] This study showed that the cumulative incidence of RP was 47.6%, which may be relatively high. In this study, however, approximately half of the patients were in non-remission status at HSCT. Furthermore, the patients who were in remission at HSCT were considered to be at a high risk for RP even after conventional procedures of transplantation. For the patients with ALL in CR2, as reported previously, the most important factors in survival after RP are the site of RP and the time to RP. 15 Several studies have suggested a survival advantage in transplantation recipients from the matched siblings, which were compared with those treated with maintenance chemotherapy. 21, 22 In a study from Nordic countries, there was no difference in outcome between the BMT and chemotherapy groups for children with late RP, and the author concluded that matched related BMT should be performed in children who experience a RP in BM during therapy or within 6 months of discontinuing therapy. 23 With the limited availability of suitable related donors, the BFM (Berlin-FrankfurtMu¨nster) RP Study Group demonstrated that unrelated donor transplantation provided significantly superior DFS as compared with chemotherapy for patients in high-risk group, based on the time and site of RP and the blast immunophenotype. 24 According to these results, among the children with ALL in CR2, only the patients in risk group S3 or S4 as per the BFM protocol for relapsed ALL were analyzed as 'high-risk' patients in our study. In addition, only the patients with AML in non-remission states at the time of HSCT were analyzed in this study. Given the patient population, the RP rate appeared to be consistent with other reports in which RP rates of 42-74% in refractory diseases have been reported. 2, 4, 17 The regimen was well tolerated, with only the common side effects of grade I and II oral mucosa and liver toxicity observed. Most patients required a continuous i.v. narcotic drug against oral pain caused by grade II mucosal toxicity. However, these symptoms improved and disappeared soon after engraftment in all engrafted patients. There are 12 grade I and II liver toxicities. As HSCT recipients were on many medications, such as antibiotics that display hepatotoxicity, it was difficult to evaluate whether these toxicities were related to the conditioning regimen. One patient developed a grade IV VOD. It was also difficult to examine the association between the VOD and the regimen because this fatal toxicity followed to acute GVHD of grade IV with Table 3 Regimen-related toxicity according to Bearman's grading system stage 4 liver disease. It is well known that the major toxicity of L-PAM is renal dysfunction. Despite starting CsA or FK506 administration on day À1 (the next day of the last L-PAM administration) in most of our patients, only a mild increase in serum creatinine levels was observed in two patients. Considering GVHD, most patients in this series received unrelated BMT, and the incidence of grade III-IV acute GVHD and chronic GVHD was similar to that in other reports. 25, 26 As a result, the TRM rate of 21.5% was comparable to or lower than those reported in other studies 2, 3, 6 and the tolerability and safety of this regimen could be demonstrated. It is noteworthy that TRM occurred in only 1 patient among 11 patients who were not in remission at HSCT. The regimen might be of benefit from a safety point of view to reduce TRM even in non-CR patients. The low incidence of TRM would contribute to relatively better outcome.
To improve DFS for advanced pediatric hematological malignancies, a novel strategy to lessen RP after HSCT will be needed. However, further intensification of the conditioning regimen has generally resulted in an increase in TRM, preventing any anti-leukemic benefits. The TBI and L-PAM regimen may provide a sufficient anti-leukemic effect without increased RRT. The limitations of this study are that it was a retrospective analysis of a small number of patients, and the follow-up periods of the survivors are too short thus far to draw any definitive conclusions. Therefore, further large-scale studies with a long-term follow-up duration are needed to better evaluate the efficacy of this regimen.
